With Nerandomilast, Boehringer Ingelheim presents a groundbreaking drug candidate that could transform the treatment of pulmonary fibrosis. Phase III studies show first positive results in over a decade.
The Munich court has overturned the ban on FOCUS doctor seals—recommended physicians may continue to display their distinction publicly.
The OTC market saw solid growth again in 2024, affirming its role as a key pillar of Germany’s healthcare system. Every second medicine sold in pharmacies is now non-prescription.
Following a record year for startup funding in 2024, Germany’s biotech industry is now facing declining revenues and a sudden drop in investor interest in early 2025.
According to the latest WIdOmonitor by AOK, public awareness of environmental risks and their impact on health is steadily declining. Air pollution in particular is viewed with less concern.
The German Paul-Ehrlich-Institut is countering vaccine misinformation with a new digital campaign: #ImpfstoffFakten (VaccinationFacts) vs. Myths.
An innovative platform that offers a compliant way for HCP verification combined with a powerful pharma and healthcare marketing toolkit.
